Pulmonary newco Synspira raises $8M

Pulmonary newco Synspira (Boston, Mass.) raised $8 million from an undisclosed investor. The company expects to start a Phase I study in early 2018 of lead candidate SNSP113 to treat exacerbations and infections in cystic fibrosis.

SNSP113 is an inhaled glycopolymeric agent that disrupts cohesion of bacterial biofilms and thick mucus in the lungs, with the goal of making antibiotics more effective. CEO Shenda Baker told BioCentury that Synspira plans to develop SNSP113 initially as an adjunct therapy to standard of care to improve outcomes in CF patients. ...